Unnamed: 0,title,date,stock,sentiment
27280.0,33 Stocks Moving in Monday's Pre-Market Session,2020-06-08 07:15:00-04:00,ADMS,neutral
27281.0,102 Biggest Movers From Friday,2020-06-08 04:54:00-04:00,ADMS,neutral
27282.0,75 Stocks Moving In Friday's Mid-Day Session,2020-06-05 12:18:00-04:00,ADMS,neutral
27283.0,"The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid",2020-06-05 07:34:00-04:00,ADMS,positive
27284.0,40 Stocks Moving in Friday's Pre-Market Session,2020-06-05 07:24:00-04:00,ADMS,neutral
27285.0,Adamas Announces FDA Filing Acceptance Of sNDA To Modify The Indication Statement For GOCOVRI To Include Treatment For Parkinson's Disease Patients Receiving Levodopa And Experiencing OFF Episodes,2020-06-04 16:31:00-04:00,ADMS,positive
27286.0,"Adamas Announces Issuance Of New US Patent For Gocovri In Parkinson's Disease, Expands Coverage With Reduction Of 'Off' Time And Increased 'Good ON' Time",2020-05-13 09:15:00-04:00,ADMS,positive
27287.0,96 Biggest Movers From Friday,2020-05-11 05:14:00-04:00,ADMS,neutral
27288.0,70 Stocks Moving In Friday's Mid-Day Session,2020-05-08 12:43:00-04:00,ADMS,neutral
27289.0,"Adamas Pharmaceuticals Q1 EPS $(0.590) Beats $(0.790) Estimate, Sales $14.481M Miss $15.360M Estimate",2020-05-07 16:14:00-04:00,ADMS,negative
27290.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,ADMS,negative
27291.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ADMS,neutral
27292.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,ADMS,negative
27293.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,ADMS,negative
27294.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,ADMS,negative
27295.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,ADMS,positive
27296.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,ADMS,negative
27297.0,"Adamas Pharmaceuticals Q4 EPS $(0.83) Beats $(0.85) Estimate, Sales $16.348M Beat $15.81M Estimate",2020-02-25 16:17:00-05:00,ADMS,neutral
27298.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,ADMS,negative
27299.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,ADMS,neutral
27300.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,ADMS,positive
27301.0,Adamas Pharma Highlights Publication Of 2-Year Phase 3 Open-Label EASE LID 2 Trial Of GOCOVRI For Dyskinesia In Patients With Parkinson's Disease,2020-02-11 16:20:00-05:00,ADMS,positive
27302.0,70 Biggest Movers From Friday,2020-01-27 04:02:00-05:00,ADMS,neutral
27303.0,54 Biggest Movers From Yesterday,2020-01-09 04:47:00-05:00,ADMS,neutral
27304.0,40 Stocks Moving In Wednesday's Mid-Day Session,2020-01-08 12:15:00-05:00,ADMS,neutral
27305.0,Adamas Announces Settlement of Patent Litigation with Sandoz Inc.; Co. Grants Sandoz License For Its Generic Version Of GOCOVRI,2020-01-02 09:01:00-05:00,ADMS,neutral
27306.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,ADMS,neutral
27307.0,64 Biggest Movers From Yesterday,2019-12-19 05:03:00-05:00,ADMS,neutral
27308.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-12-18 12:04:00-05:00,ADMS,neutral
27309.0,68 Biggest Movers From Yesterday,2019-12-18 04:56:00-05:00,ADMS,neutral
27310.0,Mid-Afternoon Market Update: Crude Oil Rises Over 1%; ImmunoGen Shares Spike Higher,2019-12-17 14:20:00-05:00,ADMS,negative
27311.0,"UPDATE: Cantor Fitzgerald Reiterates Neutral On Adamas Pharmaceuticals, Lowers Target To $7 Notes 'INROADS P3 Doesn't Lead to Gocovri Label-Expansion Inroads, Yet'; Firm Sees Possible Clarity 'by mid-20'",2019-12-17 12:48:00-05:00,ADMS,positive
27312.0,"Cantor Fitzgerald Reiterates Neutral on Adamas Pharmaceuticals, Lowers Price Target to $7",2019-12-17 12:35:00-05:00,ADMS,negative
27313.0,Mid-Day Market Update: Tallgrass Energy Jumps Following Acquisition News; Proteostasis Therapeutics Shares Plummet,2019-12-17 12:04:00-05:00,ADMS,positive
27314.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-12-17 12:01:00-05:00,ADMS,neutral
27315.0,Adamas Pharmaceuticals shares are trading lower after the company reported its Phase 3 trial of ADS-5102 for multiple sclerosis patients with walking impairments did not show significant effect on secondary walking measures despite achieving the primary endpoint.,2019-12-17 11:52:00-05:00,ADMS,negative
27316.0,"Hearing Evercore ISI Reiterating A $45 Price Target On Adamas Pharma, Following News Tues. Phase 3 Trial Of ADS-5102 Did Not Meet Primary Endpoint, Firm Highlights Belief Issue With Trial Could Be 'the final of many mistakes from prior mgmt...'",2019-12-17 11:10:00-05:00,ADMS,negative
27317.0,Mid-Morning Market Update: Markets Edge Higher; Jabil Beats Q1 Expectations,2019-12-17 10:24:00-05:00,ADMS,neutral
27318.0,"Adamas Pharmaceuticals Shares Resume Trade, Now Halted Again On Circuit Breaker",2019-12-17 09:52:00-05:00,ADMS,positive
27319.0,Adamas Pharmaceuticals Shares To Resume Trade At 9:50 a.m. EDT,2019-12-17 09:15:00-05:00,ADMS,positive
27320.0,Adamas Pharmaceuticals To Assess Potential For ADS-5102 Before Deciding Continued Investment In Program,2019-12-17 09:02:00-05:00,ADMS,neutral
27321.0,Adamas Pharmaceuticals Announces INROADS Phase 3 Trial Of ADS-5102 For Multiple Sclerosis Patients With Walking Impairment Achieved Primary Endpoint But Did Not Demonstrate Significant Effect On Secondary Walking Measures,2019-12-17 09:01:00-05:00,ADMS,negative
27322.0,Adamas Pharmaceuticals Shares Halted News Pending,2019-12-17 08:57:00-05:00,ADMS,positive
27323.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-12-04 07:24:00-05:00,ADMS,neutral
27324.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,ADMS,negative
27325.0,Adamas Pharmaceuticals Inc Files For Common Stock Offering Of Up To $50M,2019-12-03 16:14:00-05:00,ADMS,neutral
27326.0,80 Biggest Movers From Friday,2019-11-11 04:51:00-05:00,ADMS,neutral
27327.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,ADMS,neutral
27328.0,"Adamas Pharmaceuticals Q3 EPS $(0.99) Misses $(0.89) Estimate, Sales $13.933M Miss $14.07M Estimate",2019-11-07 16:35:00-05:00,ADMS,negative
27329.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,ADMS,negative
27330.0,58 Biggest Movers From Friday,2019-10-14 03:51:00-04:00,ADMS,neutral
27331.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,ADMS,positive
27332.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-10 11:08:00-04:00,ADMS,negative
27333.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,ADMS,neutral
27334.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-09 12:55:00-04:00,ADMS,negative
27335.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,ADMS,negative
27336.0,42 Biggest Movers From Yesterday,2019-10-09 05:05:00-04:00,ADMS,neutral
27337.0,45 Biggest Movers From Friday,2019-10-07 06:11:00-04:00,ADMS,neutral
27338.0,"The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering",2019-10-04 07:32:00-04:00,ADMS,negative
27339.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-03 13:03:00-04:00,ADMS,negative
27340.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,ADMS,negative
27341.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,ADMS,positive
27342.0,52 Biggest Movers From Yesterday,2019-10-02 04:22:00-04:00,ADMS,neutral
27343.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,ADMS,negative
27344.0,58 Biggest Movers From Yesterday,2019-10-01 05:56:00-04:00,ADMS,neutral
27345.0,31 Stocks Moving In Monday's Mid-Day Session,2019-09-30 13:13:00-04:00,ADMS,neutral
27346.0,Mid-Day Market Update: Thor Industries Surges On Earnings Beat; Benitec Biopharma Shares Slide,2019-09-30 13:12:00-04:00,ADMS,positive
27347.0,"Benzinga's Top Upgrades, Downgrades For September 30, 2019",2019-09-30 09:58:00-04:00,ADMS,positive
27348.0,Bank of America Downgrades Adamas Pharmaceuticals to Underperform,2019-09-30 06:41:00-04:00,ADMS,neutral
27349.0,Adamas Announces New Safety And Efficacy Data For GOCOVRI In Parkinson's Disease Patients With Dyskinesia At Movement Disorder Society 2019 International Congress,2019-09-20 08:02:00-04:00,ADMS,neutral
27350.0,Adamas Pharma Names Neil McFarlane CEO; David Mahoney Named Chair,2019-09-13 07:30:00-04:00,ADMS,neutral
27351.0,"Benzinga's Top Upgrades, Downgrades For September 9, 2019",2019-09-09 09:59:00-04:00,ADMS,positive
27352.0,"Cantor Fitzgerald Initiates Coverage On Adamas Pharmaceuticals with Neutral Rating, Announces $8 Price Target",2019-09-09 06:48:00-04:00,ADMS,neutral
27353.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,ADMS,negative
27354.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,ADMS,neutral
27355.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,ADMS,neutral
27356.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,ADMS,neutral
27357.0,35 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-07-25 05:55:00-04:00,ADMS,neutral
27358.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-07-02 08:07:00-04:00,ADMS,neutral
27359.0,"Adamas Pharma 13G Filing From Stonepine Capital Shows Raised Stake From ~984K Shares To ~1.52M Shares, Or 5.5%",2019-06-19 14:16:00-04:00,ADMS,positive
27360.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,ADMS,positive
27361.0,"The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana",2019-06-12 07:34:00-04:00,ADMS,neutral
27362.0,28 Stocks Moving In Wednesday's Pre-Market Session,2019-05-29 08:16:00-04:00,ADMS,neutral
27363.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-05-16 12:36:00-04:00,ADMS,neutral
27364.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,ADMS,negative
27365.0,"Adamas Pharmaceuticals Q1 EPS $(1.08) Beats $(1.15) Estimate, Sales $11.665M Miss $12.31M Estimate",2019-05-09 16:36:00-04:00,ADMS,negative
27366.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,ADMS,neutral
27367.0,Adamas Announces Data Presentations at #AAN2019,2019-05-07 03:53:00-04:00,ADMS,neutral
27368.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,ADMS,positive
27369.0,"The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering",2019-04-10 07:32:00-04:00,ADMS,positive
27370.0,"The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut",2019-04-04 07:58:00-04:00,ADMS,neutral
27371.0,"The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO",2019-03-28 07:54:00-04:00,ADMS,neutral
27372.0,"The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs",2019-03-26 07:36:00-04:00,ADMS,positive
27373.0,71 Biggest Movers From Yesterday,2019-03-06 04:57:00-05:00,ADMS,neutral
27374.0,Mid-Afternoon Market Update: YY Rises After Q4 Results; Atlas Financial Shares Fall,2019-03-05 14:32:00-05:00,ADMS,positive
27375.0,56 Stocks Moving In Tuesday's Mid-Day Session,2019-03-05 12:36:00-05:00,ADMS,neutral
27376.0,Mid-Day Market Update: Ctrip.Com Climbs Following Upbeat Q4 Results; Barnes & Noble Education Shares Slide,2019-03-05 12:15:00-05:00,ADMS,positive
27377.0,Mid-Morning Market Update: Markets Open Lower; Target Tops Q4 Expectations,2019-03-05 10:25:00-05:00,ADMS,positive
27378.0,10 Biggest Price Target Changes For Tuesday,2019-03-05 10:10:00-05:00,ADMS,neutral
27379.0,Needham Downgrades Adamas Pharmaceuticals to Hold,2019-03-05 09:53:00-05:00,ADMS,neutral
27380.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2019",2019-03-05 09:12:00-05:00,ADMS,positive
27381.0,36 Stocks Moving In Tuesday's Pre-Market Session,2019-03-05 08:05:00-05:00,ADMS,neutral
27382.0,Adamas Pharmaceuticals shares are trading lower;  the company reportedly suspended 2019 revenue guidance amid expected near-term unevenness in prescription growth and challenges related to plan switches. Multiple analysts downgraded the stock,2019-03-05 08:02:00-05:00,ADMS,negative
27383.0,"The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings",2019-03-05 07:24:00-05:00,ADMS,positive
27384.0,"Cowen & Co. Downgrades Adamas Pharmaceuticals to Market Perform, Lowers Price Target to $15",2019-03-05 07:05:00-05:00,ADMS,negative
27385.0,"Mizuho Downgrades Adamas Pharmaceuticals to Underperform, Lowers Price Target to $5",2019-03-05 06:42:00-05:00,ADMS,negative
27386.0,"Adamas Pharmaceuticals, Inc. - Common Stock Q4 EPS $(1.06) Beats $(1.34) Estimate, Sales $13.315M Beat $13.26M Estimate",2019-03-04 16:36:00-05:00,ADMS,neutral
27387.0,"Earnings Scheduled For March 4, 2019",2019-03-04 03:32:00-05:00,ADMS,neutral
27388.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-03-03 09:41:00-05:00,ADMS,neutral
27389.0,"Adamas Expects Net Sales of GOCOVRI to be ~$13.3M for Q4 Ended December 31, 2018;  Preliminary FY Unaudited Net Sales of GOCOVRI Expected to be ~$34M",2019-01-06 13:25:00-05:00,ADMS,neutral
27390.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,ADMS,negative
27391.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,ADMS,positive
27392.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,ADMS,positive
27393.0,Adamas Announces Issuance Of New U.S. Patent Covering GOCOVRI,2018-12-18 16:31:00-05:00,ADMS,neutral
27394.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,ADMS,positive
27395.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,ADMS,negative
27396.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,ADMS,negative
27397.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018",2018-11-20 09:12:00-05:00,ADMS,negative
27398.0,"The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings",2018-11-20 08:29:00-05:00,ADMS,negative
27399.0,"Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018",2018-11-19 10:16:00-05:00,ADMS,negative
27400.0,"Leerink Swann Initiates Coverage On Adamas Pharmaceuticals with Outperform Rating, Announces $20 Price Target",2018-11-13 08:45:00-05:00,ADMS,neutral
27401.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,ADMS,positive
27402.0,10 Biggest Price Target Changes For Monday,2018-11-05 09:51:00-05:00,ADMS,neutral
27403.0,"Benzinga's Top Upgrades, Downgrades For November 5, 2018",2018-11-05 09:05:00-05:00,ADMS,positive
27404.0,"Mizuho Downgrades Adamas Pharmaceuticals to Neutral, Lowers Price Target to $18",2018-11-05 06:05:00-05:00,ADMS,negative
27405.0,74 Biggest Movers From Friday,2018-11-05 04:36:00-05:00,ADMS,neutral
27406.0,64 Stocks Moving In Friday's Mid-Day Session,2018-11-02 12:44:00-04:00,ADMS,neutral
27407.0,"Adamas Pharmaceuticals Q3 EPS $(1.22) Beats $(1.34) Estimate, Sales $10.6M Beat $10.17M Estimate",2018-11-01 16:44:00-04:00,ADMS,neutral
27408.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,ADMS,negative
27409.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,ADMS,negative
27410.0,"Stocks Which Set New 52-Week Low Friday, October 5th",2018-10-08 09:27:00-04:00,ADMS,negative
27411.0,Adamas Pharma Reports its Phase 3 Study of GOCOVRI was 'Generally Well Tolerated',2018-10-08 08:31:00-04:00,ADMS,positive
27412.0,46 Biggest Movers From Friday,2018-10-08 04:46:00-04:00,ADMS,neutral
27413.0,36 Stocks Moving In Friday's Mid-Day Session,2018-10-05 12:37:00-04:00,ADMS,neutral
27414.0,"Benzinga's Top Upgrades, Downgrades For October 5, 2018",2018-10-05 09:42:00-04:00,ADMS,positive
27415.0,"Bank of America Downgrades Adamas Pharmaceuticals to Neutral, Lowers Price Target to $25",2018-10-05 09:23:00-04:00,ADMS,negative
27416.0,Adamas Announces Publication Of Data Demonstrating Dyskinesia's Impact On Activities Of Daily Living In People With Parkinson's Disease,2018-10-04 09:03:00-04:00,ADMS,neutral
27417.0,UPDATE: Adamas Counterclaims Assert Osmotica Has Infringed Nine Adamas Patents,2018-09-24 08:59:00-04:00,ADMS,neutral
27418.0,Adamas Pharmaceuticals In 8-k Announces Co Has Filed First Amended Answer Including Infringement Counterclaims Against Osmotica Pharmaceuticals And Vertical Pharmaceuticals In Its Ongoing Litigation Concerning Osmolex,2018-09-24 08:58:00-04:00,ADMS,negative
27419.0,"Adamas Pharmaceuticals Says FAERS Data Is Consistent With Prescribing Info, As Noted By FDA, Reports Not Necessarily Casually Related",2018-08-06 15:26:00-04:00,ADMS,negative
27420.0,Adamas Pharma Shares Dip 2.7% Lower As Traders Circulate Word An FDA Site Is Listing 3 Deaths Possibly Related To The Company's Gocovri,2018-08-06 12:29:00-04:00,ADMS,neutral
27421.0,56 Stocks Moving In Friday's Mid-Day Session,2018-08-03 12:27:00-04:00,ADMS,neutral
27422.0,30 Stocks Moving In Friday's Pre-Market Session,2018-08-03 08:02:00-04:00,ADMS,neutral
27423.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,ADMS,neutral
27424.0,Adamas Pharmaceuticals shares are trading up 14.5 percent after the company beat Q2 earnings estimates,2018-08-02 17:24:00-04:00,ADMS,positive
27425.0,8 Stocks Moving In Thursday's After-Hours Session,2018-08-02 16:46:00-04:00,ADMS,neutral
27426.0,"Adamas Pharmaceuticals Q2 EPS $(1.26) Beats $(1.41) Estimate, Sales $7.565M Beat $4.86M Estimate",2018-08-02 16:04:00-04:00,ADMS,neutral
27427.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,ADMS,positive
27428.0,"H.C. Wainwright Initiates Coverage On Adamas Pharmaceuticals with Buy Rating, Announces $45 Price Target",2018-07-16 07:06:00-04:00,ADMS,neutral
27429.0,Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics,2018-05-24 09:05:00-04:00,ADMS,neutral
27430.0,"Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down",2018-05-04 08:16:00-04:00,ADMS,neutral
27431.0,"Adamas Pharmaceuticals Q1 EPS $(1.35) Beats $(1.37) Estimate, Sales $2.6M Beat $1.6M Estimate",2018-05-03 16:27:00-04:00,ADMS,neutral
27432.0,"Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss",2018-05-03 08:31:00-04:00,ADMS,negative
27433.0,Adamas Announces Final Results From Two-Year Phase 3 Open-Label Study Of GOCOVRI In Parkinson's Disease Patients With Dyskinesia,2018-04-19 08:11:00-04:00,ADMS,neutral
27434.0,"Gocovri Stabilizes Adamas Stock, Secures Another Buy Rating",2018-03-27 12:36:00-04:00,ADMS,positive
27435.0,"Benzinga's Top Upgrades, Downgrades For March 27, 2018",2018-03-27 09:40:00-04:00,ADMS,positive
27436.0,"Bank of America Initiates Coverage On Adamas Pharmaceuticals with Buy Rating, Announces $39.00 Price Target",2018-03-27 08:08:00-04:00,ADMS,neutral
27437.0,24 Stocks Moving In Tuesday's Pre-Market Session,2018-03-27 08:02:00-04:00,ADMS,neutral
27438.0,"Shares of Adamas Pharmaceuticals Up 8.3% Premarket On Earlier 8-K Filing That Said Co. Received GOCOVRI From ~390 Distinct Prescribers, Filled GOCOVRI Prescriptions For The Period Of Jan. 1st, 2018 To Feb. 28th 2018 Were 742",2018-03-12 09:24:00-04:00,ADMS,positive
27439.0,46 Biggest Movers From Yesterday,2018-02-26 05:08:00-05:00,ADMS,neutral
27440.0,40 Stocks Moving In Friday's Mid-Day Session,2018-02-23 12:26:00-05:00,ADMS,neutral
27441.0,"Adam Feuerstein Tweets: Evercore ISI's Josh Schimmer is in full panic mode on $ADMS. His note this morning could have been ripped directly from a message board post. He's making an uncertain situation worse. Rethink, Josh.",2018-02-23 11:19:00-05:00,ADMS,negative
27442.0,"Adamas Pharma Reports Q4 EPS $(1.27) vs. $(1.26) Est., Sales $568K vs. $840K Est.",2018-02-22 16:04:00-05:00,ADMS,neutral
27443.0,Adamas Pharmaceuticals Earnings Preview,2018-02-22 10:07:00-05:00,ADMS,neutral
27444.0,34 Stocks Moving In Wednesday's Mid-Day Session,2018-02-21 12:34:00-05:00,ADMS,neutral
27445.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-02-21 08:02:00-05:00,ADMS,neutral
27446.0,40 Biggest Movers From Yesterday,2018-02-21 05:38:00-05:00,ADMS,neutral
27447.0,Adamas Pharma Shares Down 18.7% Following Earlier Announcement of Action Filed In Delaware Court By Osmotica and Vertical Pharmaceuticals Companies Regarding Its OSMOLEX ER Tablets; Co. Noted Complaint Does Not Allege Patent Infringement,2018-02-20 13:57:00-05:00,ADMS,positive
27448.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-02-20 12:24:00-05:00,ADMS,neutral
27449.0,30 Stocks Moving In Tuesday's Pre-Market Session,2018-02-20 08:00:00-05:00,ADMS,neutral
27450.0,Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER,2018-02-20 04:05:00-05:00,ADMS,positive
27451.0,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,2018-02-08 09:41:00-05:00,ADMS,negative
27452.0,Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal,2018-02-01 16:13:00-05:00,ADMS,neutral
27453.0,Adamas Pharma Prices 3M Share Offering @$41.50/Share,2018-01-23 20:31:00-05:00,ADMS,positive
27454.0,"10 Stocks To Watch For January 23, 2018",2018-01-23 04:38:00-05:00,ADMS,neutral
27455.0,11 Stocks Moving In Monday's After-Hours Session,2018-01-22 17:35:00-05:00,ADMS,neutral
27456.0,Adamas Announces $85M Common Stock Offering,2018-01-22 16:02:00-05:00,ADMS,neutral
27457.0,Adamas Pharma Announces U.S. Launch Of GOCOVRI,2018-01-08 16:44:00-05:00,ADMS,neutral
27458.0,7 Stocks Ready To Climb Another 30% in 2018,2017-12-19 11:33:00-05:00,ADMS,positive
27459.0,Adamas Pharma Option Alert: Jan 19 $30 Calls Sweep (2) at the Bid: 1000 @ $7.0 vs 162 OI; Ref=$36.1,2017-12-01 13:37:00-05:00,ADMS,positive
27460.0,"Adamas Pharmaceutical Shares Up 4.64%; Hearing Northland Capital Earlier Initiated Coverage With Outperform Rating And $70 Price Target, Unconfirmed",2017-11-29 13:31:00-05:00,ADMS,positive
27461.0,Adamas Shares Volatile Off The Open As Traders Circulate Unconfirmed Chatter Of M&A Interest,2017-11-08 09:44:00-05:00,ADMS,positive
27462.0,"Adamas Pharmaceuticals Reports Q3 EPS $(1.04) vs $(0.98) Est., Sales $1K vs $30K Est.",2017-11-02 16:58:00-04:00,ADMS,neutral
27463.0,"Adamas Pharma's Gocovri Will Achieve 'Blockbuster' Status, Says Kerrisdale",2017-11-01 11:29:00-04:00,ADMS,neutral
27464.0,"Kerrisdale Capital Says Adamas Pharmaceutical Lead Drug Gocovri Will Achieve 'Blockbuster' Status, Says Earlier-Stage Pipeline Assets Alone Are Worth Billions",2017-11-01 09:07:00-04:00,ADMS,positive
27465.0,Adamas Pharma 13G Filing From Kerrisdale Shows 6.5% Stake,2017-11-01 08:35:00-04:00,ADMS,neutral
27466.0,40 Biggest Movers From Yesterday,2017-10-31 04:54:00-04:00,ADMS,neutral
27467.0,Adamas Pharmaceuticals Sharply Higher Off New Outperform Rating,2017-10-30 12:48:00-04:00,ADMS,neutral
27468.0,35 Stocks Moving In Monday's Mid-Day Session,2017-10-30 12:30:00-04:00,ADMS,neutral
27469.0,"Benzinga's Top Upgrades, Downgrades For October 30, 2017",2017-10-30 09:22:00-04:00,ADMS,positive
27470.0,"Evercore ISI Group Initiates Coverage On Adamas Pharmaceuticals with Outperform Rating, Announces $85.00 Price Target",2017-10-30 08:44:00-04:00,ADMS,neutral
27471.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-30 08:05:00-04:00,ADMS,neutral
27472.0,Benzinga's Option Alert Recap From October 4,2017-10-04 16:22:00-04:00,ADMS,positive
27473.0,Adamas Option Alert: Dec 15 $22.5 Calls Sweep (9) at the Ask: 614 @ $2.65 vs 459 OI; Ref=$22.1,2017-10-04 15:46:00-04:00,ADMS,positive
27474.0,10 Biggest Mid-Day Gainers For Tuesday,2017-09-19 12:27:00-04:00,ADMS,neutral
27475.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-19 08:10:00-04:00,ADMS,neutral
27476.0,"Adamas Pharmaceuticals, Hi-Crush Partners Holding Analyst/Investor Days Today",2017-09-18 08:53:00-04:00,ADMS,neutral
27477.0,"Adamas Reports Topline Phase 1b Data of ADS-4101, Was Safe And Well-Tolerated Across All 3 Doses",2017-09-07 08:32:00-04:00,ADMS,positive
27478.0,Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts,2017-09-01 14:03:00-04:00,ADMS,neutral
27479.0,Mid-Afternoon Market Update: GameStop Drops After Mixed Q2 Report; Pure Storage Shares Surge,2017-08-25 14:33:00-04:00,ADMS,positive
27480.0,18 Biggest Mid-Day Gainers For Friday,2017-08-25 12:17:00-04:00,ADMS,neutral
27481.0,Adamas Up 40% After FDA Approval Of Gocovri,2017-08-25 12:12:00-04:00,ADMS,positive
27482.0,"Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments",2017-08-25 12:03:00-04:00,ADMS,positive
27483.0,Mid-Day Market Update: Adamas Pharma Climbs Following FDA Approval of GOCOVRI; Aceto Shares Plummet,2017-08-25 12:00:00-04:00,ADMS,positive
27484.0,Mid-Morning Market Update: Markets Open Higher; Big Lots Profit Tops Estimates,2017-08-25 10:09:00-04:00,ADMS,positive
27485.0,22 Stocks Moving In Friday's Pre-Market Session,2017-08-25 08:02:00-04:00,ADMS,neutral
27486.0,Adamas Pharma +49% Premarket @$21.20 Following Announcement of FDA Approval of GOCOVRI,2017-08-25 04:34:00-04:00,ADMS,positive
27487.0,"Adamas Pharma Shares Resume Trade, Now Up 40%",2017-08-24 16:45:00-04:00,ADMS,positive
27488.0,Adamas Pharma Shares To Resume Trade At 4:45 p.m. EDT,2017-08-24 16:44:00-04:00,ADMS,positive
27489.0,Adamas Pharma Resumes @4:45 PM ET,2017-08-24 16:33:00-04:00,ADMS,neutral
27490.0,Adamas Pharma Reports FDA Approval Of GOCOVRI For Treatment Of Dyskinesia In Parkinson's Patients,2017-08-24 16:16:00-04:00,ADMS,positive
27491.0,"UPDATE: Adamas Pharma Shares Closed Down 1%, Now Halted With News Pending Ahead Of PDUFA Decision",2017-08-24 16:01:00-04:00,ADMS,positive
27492.0,Adamas Pharma Shares Halted News Pending,2017-08-24 16:00:00-04:00,ADMS,positive
27493.0,REMINDER: Adamas Pharmaceuticals Has PDUFA Date For ADS-5102 Today,2017-08-24 08:44:00-04:00,ADMS,neutral
27494.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-08-24 08:12:00-04:00,ADMS,neutral
27495.0,"Adamas Pharmaceuticals Reports Q2 EPS $(0.93) vs $(0.81) Est., Sales $2K vs $40K Est.",2017-08-08 16:45:00-04:00,ADMS,neutral
27496.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,ADMS,neutral
27497.0,Adamas Pharma Names Alfred Merriweather CFO,2017-06-28 09:01:00-04:00,ADMS,neutral
27498.0,A Peek At Adamis Ahead Of FDA Approval,2017-06-15 09:05:00-04:00,ADMS,positive
27499.0,Adamas Pharma Offers Results From ADS-5102 EASE LID Trial: 'Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson's Disease Patients with Levodopa-induced Dyskinesia',2017-06-12 16:04:00-04:00,ADMS,positive
27501.0,"Adamas Pharma Reports Expansion Of ADS-5102 Open-Label Study Showing Tolerability, Durability Out To 18 Weeks",2017-06-08 16:11:00-04:00,ADMS,neutral
27502.0,Watch These 7 Huge Call Purchases In Monday Trade,2017-06-05 04:19:00-04:00,ADMS,positive
27503.0,Adamas Phase 1 Results Show ADS-4101 IS Better Tolerated In Healthy Volunteers Than Equivalent Doses Of VIMPAT Immediate Release Tablets,2017-05-22 08:34:00-04:00,ADMS,positive
27504.0,Adamas Signs $100M Royalty-Backed Note Agreement with HealthCare Royalty Partners,2017-05-11 09:14:00-04:00,ADMS,positive
27505.0,Adamas Pharmaceuticals Reports Q1 EPS $(0.72) vs $(0.71) Est.,2017-05-09 16:56:00-04:00,ADMS,neutral
27506.0,Adamas Names Richard King COO,2017-04-27 17:52:00-04:00,ADMS,neutral
27507.0,"Adamas Pharma Reports Pooled Phase 3 Data for ADS-5102 Confirmed Statistical Significant Reduction in Levodopa-Induced Dyskinesia, OFF Time in People with Parkinson's",2017-04-24 09:13:00-04:00,ADMS,positive
27508.0,"Adamas Reports Q4 EPS $(0.68) vs $(0.80) Est., Sales $37K vs $190K Est.",2017-02-28 16:45:00-05:00,ADMS,neutral
27509.0,Adamas Pharma Sells off to Low of $14.35 on Volume,2017-01-30 14:28:00-05:00,ADMS,negative
27510.0,Adamas Pharmaceuticals Says Preparing for Potential Approval and Commercialization of ADS-5102,2017-01-08 21:26:00-05:00,ADMS,positive
27511.0,Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia,2017-01-06 09:00:00-05:00,ADMS,positive
27512.0,Stifel Healthcare Conference Today,2016-11-15 10:53:00-05:00,ADMS,neutral
27513.0,"Adamas Reports Q3 Loss/Share $0.66 vs Est Loss/Share $0.82, Revenue $138K vs $220K Est",2016-11-03 18:01:00-04:00,ADMS,neutral
27514.0,Adamas Submits New Drug Application to U.S. FDA for ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease,2016-10-27 08:09:00-04:00,ADMS,neutral
27515.0,"25 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-22 09:47:00-04:00,ADMS,neutral
27516.0,"Allergan, Adamas Report U.S. Availability of New Dosage Strengths for NAMZARIC XR",2016-09-22 08:02:00-04:00,ADMS,positive
27517.0,"After-Hours Gainers Sept. 20, 2016: CLVS Up 10.3%, ADMS 6.1%, SPSC 5.6%, ADBE 5%, FDX 2.7%, KBH 2.2%, MSFT 1%, SRPT 1%",2016-09-20 17:59:00-04:00,ADMS,neutral
27518.0,Adamas Reports EASE LID 3 Meets Primary And Secondary Endpoints,2016-09-20 16:11:00-04:00,ADMS,positive
27519.0,25 Stocks Which Rallied Three Days,2016-09-16 08:04:00-04:00,ADMS,neutral
27520.0,15 Stocks With Three-Day Increasing Volume,2016-09-16 06:58:00-04:00,ADMS,neutral
27521.0,20 Stocks Which Rallied Three Days,2016-09-15 11:05:00-04:00,ADMS,neutral
27522.0,"Director Ericson Buys 50,919 Shares of Adamas Pharmaceuticals @$14.79/Share -Form 4",2016-09-08 04:33:00-04:00,ADMS,positive
27523.0,"Allergan, Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation; Forest & Adamas To Grant Amneal A License To Market Generic Namzaric Beginning Jan. 1, 2025",2016-08-31 08:02:00-04:00,ADMS,positive
27524.0,Adamas Pharmaceuticals Reports Q2 EPS $(0.78) vs. Est. $(0.71),2016-08-04 17:03:00-04:00,ADMS,neutral
27525.0,Adamas Shares Trading Up To $16.20/Share Pre-market,2016-07-19 08:00:00-04:00,ADMS,positive
27526.0,Allergan and Adamas Announce New Expanded Indication for NAMZARIC Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease,2016-07-19 07:59:00-04:00,ADMS,negative
27527.0,Adamas Pharma Says Additional Phase 3 Clinical Program of ADS-5102 Extended-Release Capsules,2016-06-22 06:03:00-04:00,ADMS,neutral
27528.0,Adamas Pharma Shares Up ~2% Following Earlier Upgrade to Buy from Mizuho,2016-06-16 09:41:00-04:00,ADMS,positive
27529.0,Adamas Pharma Reports Results from Phase 2 Proof-of-Concept Study of ADS-5102 for Treatment of Walking Impairment in MS Patients: Data Supports Further Clinical Development,2016-06-13 08:01:00-04:00,ADMS,positive
27530.0,"Adamas Reports Q1 EPS $(0.65) vs. Est. $(0.76), Rev. $175K vs. Est. $320K",2016-05-10 16:59:00-04:00,ADMS,neutral
27531.0,12 Stocks Moving In Wednesday's Pre-Market Session,2016-05-04 08:32:00-04:00,ADMS,neutral
27532.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-04-28 08:21:00-04:00,ADMS,neutral
27533.0,"Adamas Reports PHase 3 EASE LID Meets Primary & Secondary Endpoints, Showed Statistically Significant Improvement In LID At 12 Weeks And  Decrease In OFF Time vs. Placebo",2016-04-28 07:27:00-04:00,ADMS,positive
27534.0,Adamas Presents Positive Findings from Phase 3 EASE LID Clinical Trial of ADS-5102 for Treatment of Levodopa-induced Dyskinesia Associated with Parkinson's Disease at AACR,2016-04-20 04:56:00-04:00,ADMS,positive
27535.0,Benzinga's Top Initiations,2016-04-01 09:32:00-04:00,ADMS,positive
27536.0,"JMP Securities Initiates Coverage on Adamas Pharmaceuticals at Market Outperform, Announces $29.00 PT",2016-04-01 07:06:00-04:00,ADMS,positive
27537.0,"Adamas Pharma Reports Q4 EPS $(0.58) vs $(0.94) Est., Sales $524K vs $200K Est.",2016-02-23 16:08:00-05:00,ADMS,neutral
27538.0,Benzinga's Top Initiations,2016-01-19 09:55:00-05:00,ADMS,positive
27539.0,"Cowen & Company Initiates Coverage on Adamas Pharmaceuticals at Outperform, Announces $45.00 PT",2016-01-19 07:52:00-05:00,ADMS,neutral
27540.0,"Mizuho Securities Initiates Coverage on Adamas Pharmaceuticals at Neutral, Announces $26.00 PT",2016-01-19 07:51:00-05:00,ADMS,positive
27541.0,Here's Why There's Been A Rush Of Biotech Offerings,2016-01-07 11:32:00-05:00,ADMS,neutral
27542.0,Adamas Prices 2.5M Share Offering @$23.00/Share,2016-01-07 04:09:00-05:00,ADMS,positive
27543.0,UPDATE: Filing from Adamas Shows Forest Labs Expects to Appeal Adverse District Court Ruling at the Appropriate Time,2016-01-06 06:14:00-05:00,ADMS,negative
27544.0,"8-K from Adamas Pharma Shows District Court Issued Markman Ruling in Litigation from Forest Labs, Merz Pharm Filed Against Several Cos. Related to ANDAs for Generic Namenda XR",2016-01-06 06:12:00-05:00,ADMS,negative
27545.0,Adamas Reports Offering of 2.5M Common Shares,2016-01-05 07:15:00-05:00,ADMS,positive
27546.0,Mid-Afternoon Market Update: Dow Surges Over 1%; Bed Bath & Beyond Shares Slip On Lowered Q3 Outlook,2015-12-23 15:03:00-05:00,ADMS,positive
27547.0,Mid-Day Market Update: Crude Oil Down 4%; Adamas Pharmaceuticals Shares Jump Following Positive Phase 3 Results,2015-12-23 12:34:00-05:00,ADMS,positive
27548.0,Benzinga's Volume Movers,2015-12-23 10:28:00-05:00,ADMS,neutral
27549.0,Mid-Morning Market Update: Markets Open Higher; Nike Profit Tops Expectations,2015-12-23 10:09:00-05:00,ADMS,positive
27550.0,Adamas Pharmaceuticals Surges 30% Following Positive Phase 3 Results,2015-12-23 08:49:00-05:00,ADMS,positive
27551.0,Benzinga's Top #PreMarket Gainers,2015-12-23 08:08:00-05:00,ADMS,positive
27552.0,Adamas Announces Positive Top Line Phase 3 Results for ADS-5102,2015-12-23 06:01:00-05:00,ADMS,positive
27553.0,Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease,2015-12-23 06:00:00-05:00,ADMS,positive
27554.0,"Adamas Reports Q3 EPS ($0.81) vs. Est. ($0.84), Rev. $768K vs. Est. $90K",2015-11-12 16:27:00-05:00,ADMS,neutral
27555.0,"UPDATE: Adamas Senior VP, Product Development Says With Improved ADS-5102 Profile, 'we can potentially administer higher therapeutic doses than is common with immediate release amantadine'",2015-10-12 16:01:00-04:00,ADMS,positive
27556.0,Adamas Presents Nonclinical Findings Supporting the Potential Use of ADS-5102 for the Treatment of Multiple Sclerosis Gait,2015-10-12 16:00:00-04:00,ADMS,positive
27557.0,Why Aegis Capital Loves Adamas...And How To Bet On Parkinson's Treatment,2015-09-22 11:17:00-04:00,ADMS,positive
27558.0,"Aegis Capital Initiates Coverage on Adamas Pharmaceuticals at Buy, Announces $29.00 PT",2015-09-22 09:19:00-04:00,ADMS,neutral
27559.0,"Adamas Pharma Reports Q2 Loss $0.78 Vs Est Loss $0.72, Sales $398K vs Est $30.00K",2015-08-11 16:05:00-04:00,ADMS,negative
27560.0,Adamas Finishes Recruitment of Its Phase 3 EASE LID Study Evaluating ADS-5102 for the Treatment of Levodopa-induced Dyskinesia Associated With Parkinson's Disease,2015-07-09 16:10:00-04:00,ADMS,positive
27561.0,Adamas Pharmaceuticals Issued U.S. Patent Relating to ADS-5102 Program,2015-07-07 16:00:00-04:00,ADMS,neutral
27562.0,Adamas Starts Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients With Walking Impairment,2015-06-11 16:02:00-04:00,ADMS,neutral
27563.0,2 Small Cap Pharma Stocks Credit Suisse Loves,2015-05-27 11:10:00-04:00,ADMS,positive
27564.0,Adamas Pharmaceuticals Files for Up to $150M Stock Shelf,2015-05-19 06:07:00-04:00,ADMS,neutral
27565.0,Adamas Pharma Reports Q1 Loss of $0.69/Share vs Loss of $0.74/Share Est.,2015-05-13 16:01:00-04:00,ADMS,negative
27566.0,Adamas Pharma Announces Receiving of Orphan Drug Designation for ADS-5102,2015-04-10 08:31:00-04:00,ADMS,neutral
27567.0,Adamas Pharma Issues Patent,2015-03-31 16:01:00-04:00,ADMS,neutral
27568.0,"Adamas Reports Q4 EPS $0.53 vs. $(0.24), Rev. $55M vs. $10M",2015-03-03 16:15:00-05:00,ADMS,neutral
27569.0,"Adamas Pharmaceuticals Recaps 2014 Acheivements, Previews Upcoming Business Drivers",2015-01-11 19:30:00-05:00,ADMS,neutral
27570.0,Adamas Pharmaceuticals Receives $30M Payment From Actavis,2015-01-08 16:04:00-05:00,ADMS,neutral
27571.0,Mid-Day Market Update: Crude Oil Slides Over 1%; American Apparel Shares Jump,2014-12-26 12:58:00-05:00,ADMS,negative
27572.0,"Stocks To Watch For December 26, 2014",2014-12-26 04:28:00-05:00,ADMS,neutral
27573.0,#Premarket Prep Technical Update - Adamas Pharmaceuticals Sharply Higher,2014-12-24 10:32:00-05:00,ADMS,neutral
27574.0,Benzinga's Volume Movers,2014-12-24 10:22:00-05:00,ADMS,neutral
27575.0,Morning Market Movers,2014-12-24 09:42:00-05:00,ADMS,neutral
27576.0,"FDA Approves Adamas Pharmaceuticals' Alzheimer's Drug, Shares Soar",2014-12-24 09:26:00-05:00,ADMS,positive
27577.0,Adamas Pharmaceuticals Shares Rise 20% Premarket on FDA Approval of Alzheimer's Treatment,2014-12-24 08:57:00-05:00,ADMS,positive
27578.0,"Actavis, Adamas Report FDA Approval of Namzaric for Treatment of Moderate to Severe Alzheimer's",2014-12-24 08:01:00-05:00,ADMS,positive
27579.0,Adamas Pharmaceuticals Issued Six Additional U.S. Patents,2014-12-02 09:03:00-05:00,ADMS,neutral
27580.0,Adamas Pharmaceuticals Reports Q3 EPS of $(0.57) vs $(0.44) Est,2014-11-04 16:19:00-05:00,ADMS,neutral
27581.0,Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 ,2014-10-28 16:12:00-04:00,ADMS,positive
27582.0,5 Healthcare Stocks With The Highest Operating Margin,2014-09-23 09:23:00-04:00,ADMS,neutral
27583.0,"Adamas Pharma Names Jeff Knapp as COO, Bill Dawson Replacing Tony Rimac as CFO",2014-08-13 17:17:00-04:00,ADMS,neutral
27584.0,"Adams Pharma EPS $0.88, Rev $25.2M",2014-08-07 16:27:00-04:00,ADMS,neutral
27585.0,USPTO Issues Patent to Adamas Pharmaceuticals ,2014-08-05 16:56:00-04:00,ADMS,neutral
27586.0,"Events Scheduled for Week of Jun 23rd to Jun 27th, 2014",2014-06-23 18:25:00-04:00,ADMS,neutral
27587.0,"Adams Pharma Announces Rater Training Data on ADS-5102, Says Phase 2/3 Eased Study Met Primary Endpoint",2014-06-10 08:36:00-04:00,ADMS,positive
27588.0,Adamas Issued Patent,2014-06-09 16:02:00-04:00,ADMS,neutral
27589.0,Adamas Initiates Phase 3 Trial For ADS-5102,2014-06-09 16:02:00-04:00,ADMS,neutral
27590.0,Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE,2014-05-21 04:58:00-04:00,ADMS,positive
27591.0,Adamas Pharmaceuticals Recieves $25M Milestone Payment From Forest Labs,2014-05-20 16:06:00-04:00,ADMS,neutral
27592.0,Adamas Pharmaceuticals Reports Q1 EPS of $(0.67),2014-05-13 16:05:00-04:00,ADMS,neutral
27593.0,Benzinga's Top Initiations,2014-05-05 07:49:00-04:00,ADMS,positive
27594.0,"Needham Initiates Coverage on Adamas Pharmaceuticals at Buy, Announces $33.00 PT",2014-05-05 07:35:00-04:00,ADMS,neutral
27595.0,"William Blair Initiates Coverage on Adamas Pharmaceuticals at Outperform, Announces $35.00 PT",2014-05-05 07:35:00-04:00,ADMS,neutral
27596.0,"Piper Jaffray Initiates Coverage on Adamas Pharmaceuticals at Overweight, Announces $32.00 PT",2014-05-05 07:35:00-04:00,ADMS,negative
27597.0,"Adamas Pharmaceuticals Shareholder MDV VII LP Buys 300,000 Shares at $16.00/Share -Form 4",2014-04-16 19:24:00-04:00,ADMS,positive
27598.0,"Adamas Pharmaceuticals Announces Closing of Initial Public Offering, Estimates Net Proceeds of $41.5M",2014-04-15 16:02:00-04:00,ADMS,neutral
27599.0,"Adamas Pharmaceuticals Announces Closing of Initial Public Offering, Estimates Net Proceeds of $41.5M",2014-04-15 16:02:00-04:00,ADMS,neutral
27600.0,IPO Review For The Week Of April 7: IPOs Outperform S&P 500...Again,2014-04-12 16:05:00-04:00,ADMS,neutral
27601.0,"IPO Wrapup for the Week of April 7th, 2014",2014-04-11 16:59:00-04:00,ADMS,neutral
27602.0,"IPO Outlook for Friday, April 11: City Office, Paycom Software, Farmland Partners & More",2014-04-11 07:45:00-04:00,ADMS,neutral
27603.0,"Adamas Pharma Shares Open at $16.85/Share, Priced at $16",2014-04-10 10:25:00-04:00,ADMS,positive
27604.0,"IPO Investor Outlook For Thursday, April 10",2014-04-10 08:10:00-04:00,ADMS,neutral
27605.0,"IPO Lookout: IPOs For The Week Of April 7, 2014",2014-04-07 16:14:00-04:00,ADMS,neutral
